IL6 and systemic inflammatory response syndrome: Furthermore, deferoxamine has been found to reduce the release of inflammatory mediators including IL-6 and TNF-α, thereby mitigating tissue damage caused by systemic inflammatory response syndrome (SIRS) [69].